These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 33121914)

  • 1. Pathologic nodal downstaging in men with clinically involved lymph nodes undergoing radical prostatectomy: Implications for definitive locoregional therapy.
    Ghali F; Daly WC; Hansen M; Hayn M; Sammon J; Beaule LT; Sarkar R; Murphy J; Kader AK; Derweesh I; Rose B; Ryan ST
    Urol Oncol; 2021 Feb; 39(2):130.e1-130.e7. PubMed ID: 33121914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathologic nodal staging scores in patients treated with radical prostatectomy: a postoperative decision tool.
    Kluth LA; Abdollah F; Xylinas E; Rieken M; Fajkovic H; Sun M; Karakiewicz PI; Seitz C; Schramek P; Herman MP; Becker A; Loidl W; Pummer K; Nonis A; Lee RK; Lotan Y; Scherr DS; Seiler D; Chun FK; Graefen M; Tewari A; Gönen M; Montorsi F; Shariat SF; Briganti A
    Eur Urol; 2014 Sep; 66(3):439-46. PubMed ID: 23850255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of definitive local therapy for lymph node-positive prostate cancer: a population-based study.
    Rusthoven CG; Carlson JA; Waxweiler TV; Raben D; Dewitt PE; Crawford ED; Maroni PD; Kavanagh BD
    Int J Radiat Oncol Biol Phys; 2014 Apr; 88(5):1064-73. PubMed ID: 24661660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
    Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
    Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes after radical prostatectomy for patients with clinical stages T1-T2 prostate cancer with pathologically positive lymph nodes in the prostate-specific antigen era.
    Dorin RP; Lieskovsky G; Fairey AS; Cai J; Daneshmand S
    Urol Oncol; 2013 Nov; 31(8):1441-7. PubMed ID: 22516714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does increasing the nodal yield improve outcomes in contemporary patients without nodal metastasis undergoing radical prostatectomy?
    Kluth LA; Xylinas E; Rieken M; Chun FK; Fajkovic H; Becker A; Karakiewicz PI; Passoni N; Herman M; Lotan Y; Seitz C; Schramek P; Remzi M; Loidl W; Guillonneau B; Rouprêt M; Briganti A; Scherr DS; Graefen M; Tewari AK; Shariat SF
    Urol Oncol; 2014 Jan; 32(1):47.e1-8. PubMed ID: 24055425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical nodal staging scores for prostate cancer: a proposal for preoperative risk assessment.
    Kluth LA; Abdollah F; Xylinas E; Rieken M; Fajkovic H; Seitz C; Sun M; Karakiewicz PI; Schramek P; Herman MP; Becker A; Hansen J; Ehdaie B; Loidl W; Pummer K; Lee RK; Lotan Y; Scherr DS; Seiler D; Ahyai SA; Chun FK; Graefen M; Tewari A; Nonis A; Bachmann A; Montorsi F; Gönen M; Briganti A; Shariat SF
    Br J Cancer; 2014 Jul; 111(2):213-9. PubMed ID: 25003663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radical prostatectomy improves progression-free and cancer-specific survival in men with lymph node positive prostate cancer in the prostate-specific antigen era: a confirmatory study.
    Steuber T; Budäus L; Walz J; Zorn KC; Schlomm T; Chun F; Ahyai S; Fisch M; Sauter G; Huland H; Graefen M; Haese A
    BJU Int; 2011 Jun; 107(11):1755-61. PubMed ID: 20942833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is More Always Better? An Assessment of the Impact of Lymph Node Yield on Outcome for Clinically Localized Prostate Cancer with Low/Intermediate Risk Pathology (pT2-3a/pN0) Managed with Prostatectomy Alone.
    Seyedin SN; Mitchell DL; Mott SL; Russo JK; Tracy CR; Snow AN; Parkhurst JR; Smith MC; Buatti JM; Watkins JM
    Pathol Oncol Res; 2019 Jan; 25(1):209-215. PubMed ID: 29079967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer.
    Lughezzani G; Gallina A; Larcher A; Briganti A; Capitanio U; Suardi N; Lista G; Abrate A; Sangalli MN; Buffi N; Cestari A; Guazzoni G; Rigatti P; Montorsi F
    BJU Int; 2013 May; 111(5):723-30. PubMed ID: 22487441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of adjuvant hormonal and radiation therapy significantly prolongs survival of patients with pT2-4 pN+ prostate cancer: results of a matched analysis.
    Briganti A; Karnes RJ; Da Pozzo LF; Cozzarini C; Capitanio U; Gallina A; Suardi N; Bianchi M; Tutolo M; Salonia A; Di Muzio N; Rigatti P; Montorsi F; Blute M
    Eur Urol; 2011 May; 59(5):832-40. PubMed ID: 21354694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Definitive external-beam radiotherapy versus radical prostatectomy in clinically localized high-risk prostate cancer: a retrospective study.
    Andic F; Izol V; Gokcay S; Arslantas HS; Bayazit Y; Coskun H; Tansug MZ; Sertdemir Y
    BMC Urol; 2019 Jan; 19(1):3. PubMed ID: 30611260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Number of metastatic lymph nodes as determinant of outcome after salvage radical prostatectomy for radiation-recurrent prostate cancer.
    Gugliemetti G; Sukhu R; Conca Baenas MA; Meeks J; Sjoberg DD; Eastham JA; Scardino PT; Touijer K
    Actas Urol Esp; 2016 Sep; 40(7):434-9. PubMed ID: 27184342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical significance of pelvic lymph node status in prostate cancer: review of 1690 cases.
    Maccio L; Barresi V; Domati F; Martorana E; Cesinaro AM; Migaldi M; Iachetta F; Ieni A; Bonetti LR
    Intern Emerg Med; 2016 Apr; 11(3):399-404. PubMed ID: 26875178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of surgical volume on the rate of lymph node metastases in patients undergoing radical prostatectomy and extended pelvic lymph node dissection for clinically localized prostate cancer.
    Briganti A; Capitanio U; Chun FK; Gallina A; Suardi N; Salonia A; Da Pozzo LF; Colombo R; Di Girolamo V; Bertini R; Guazzoni G; Karakiewicz PI; Montorsi F; Rigatti P
    Eur Urol; 2008 Oct; 54(4):794-802. PubMed ID: 18514383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pelvic lymph node dissection and its extent on survival benefit in prostate cancer patients with a risk of lymph node invasion >5%: a propensity score matching analysis from SEER database.
    Chen J; Wang Z; Zhao J; Zhu S; Sun G; Liu J; Zhang H; Zhang X; Shen P; Shi M; Zeng H
    Sci Rep; 2019 Nov; 9(1):17985. PubMed ID: 31784574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence of positive pelvic lymph nodes in patients with prostate cancer, a prostate-specific antigen (PSA) level of < or =10 ng/mL and biopsy Gleason score of < or =6, and their influence on PSA progression-free survival after radical prostatectomy.
    Weckermann D; Goppelt M; Dorn R; Wawroschek F; Harzmann R
    BJU Int; 2006 Jun; 97(6):1173-8. PubMed ID: 16686707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes for Patients with Clinical Lymphadenopathy Treated with Radical Prostatectomy.
    Moschini M; Briganti A; Murphy CR; Bianchi M; Gandaglia G; Montorsi F; Quevedo JF; Carlson R; Kwon E; Karnes RJ
    Eur Urol; 2016 Feb; 69(2):193-6. PubMed ID: 26264160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Questioning the Status Quo: Should Gleason Grade Group 1 Prostate Cancer be Considered a "Negative Core" in Pre-Radical Prostatectomy Risk Nomograms? An International Multicenter Analysis.
    Leong JY; Herrera-Caceres JO; Goldberg H; Tham E; Teplitsky S; Gomella LG; Trabulsi EJ; Lallas CD; Fleshner NE; Tilki D; Chandrasekar T
    Urology; 2020 Mar; 137():102-107. PubMed ID: 31705947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolution of the presentation and pathologic and biochemical outcomes after radical prostatectomy for patients with clinically localized prostate cancer diagnosed during the PSA era.
    Ung JO; Richie JP; Chen MH; Renshaw AA; D'Amico AV
    Urology; 2002 Sep; 60(3):458-63. PubMed ID: 12350484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.